Pulmonary Sarcoidosis following Etanercept Treatment

Tumour necrosis factor (TNF) is an important cytokine involved in the pathology of a number of inflammatory conditions, and thus blockade with anti-TNF therapies is becoming the cornerstone in managing such diseases. With increasing use, evidence is collected for the association of sarcoid-like gran...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhamra, Kuljeet, Stevens, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3540653/
https://www.ncbi.nlm.nih.gov/pubmed/23320239
http://dx.doi.org/10.1155/2012/724013
_version_ 1782255235358523392
author Bhamra, Kuljeet
Stevens, Richard
author_facet Bhamra, Kuljeet
Stevens, Richard
author_sort Bhamra, Kuljeet
collection PubMed
description Tumour necrosis factor (TNF) is an important cytokine involved in the pathology of a number of inflammatory conditions, and thus blockade with anti-TNF therapies is becoming the cornerstone in managing such diseases. With increasing use, evidence is collected for the association of sarcoid-like granulomatous disease developing after the initiation of anti-TNF-α therapy, with disease reversal after discontinuation.
format Online
Article
Text
id pubmed-3540653
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-35406532013-01-14 Pulmonary Sarcoidosis following Etanercept Treatment Bhamra, Kuljeet Stevens, Richard Case Rep Rheumatol Case Report Tumour necrosis factor (TNF) is an important cytokine involved in the pathology of a number of inflammatory conditions, and thus blockade with anti-TNF therapies is becoming the cornerstone in managing such diseases. With increasing use, evidence is collected for the association of sarcoid-like granulomatous disease developing after the initiation of anti-TNF-α therapy, with disease reversal after discontinuation. Hindawi Publishing Corporation 2012 2012-12-23 /pmc/articles/PMC3540653/ /pubmed/23320239 http://dx.doi.org/10.1155/2012/724013 Text en Copyright © 2012 K. Bhamra and R. Stevens. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Bhamra, Kuljeet
Stevens, Richard
Pulmonary Sarcoidosis following Etanercept Treatment
title Pulmonary Sarcoidosis following Etanercept Treatment
title_full Pulmonary Sarcoidosis following Etanercept Treatment
title_fullStr Pulmonary Sarcoidosis following Etanercept Treatment
title_full_unstemmed Pulmonary Sarcoidosis following Etanercept Treatment
title_short Pulmonary Sarcoidosis following Etanercept Treatment
title_sort pulmonary sarcoidosis following etanercept treatment
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3540653/
https://www.ncbi.nlm.nih.gov/pubmed/23320239
http://dx.doi.org/10.1155/2012/724013
work_keys_str_mv AT bhamrakuljeet pulmonarysarcoidosisfollowingetanercepttreatment
AT stevensrichard pulmonarysarcoidosisfollowingetanercepttreatment

Ejemplares similares